Jason Aryeh - Net Worth and Insider Trading

Jason Aryeh Net Worth

The estimated net worth of Jason Aryeh is at least $9 Million dollars as of 2024-04-23. Jason Aryeh is the Director of Ligand Pharmaceuticals Inc and owns about 123,822 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $8 Million. Jason Aryeh is the Director of Novelion Therapeutics Inc and owns about 392,733 shares of Novelion Therapeutics Inc (NVLNF) stock worth over $275,699. Jason Aryeh is also the See Explanation of Responses of Merrimack Pharmaceuticals Inc and owns about 3,802 shares of Merrimack Pharmaceuticals Inc (MACK) stock worth over $56,003. Besides these, Jason Aryeh also holds Myrexis Inc (MYRX) . Details can be seen in Jason Aryeh's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jason Aryeh has not made any transactions after 2019-09-03 and currently still holds the listed stock(s).

Transaction Summary of Jason Aryeh

To

Jason Aryeh Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jason Aryeh owns 10 companies in total, including Ligand Pharmaceuticals Inc (LGND) , Merrimack Pharmaceuticals Inc (MACK) , and Old API Wind-down Ltd (ARLZQ) among others .

Click here to see the complete history of Jason Aryeh’s form 4 insider trades.

Insider Ownership Summary of Jason Aryeh

Ticker Comapny Transaction Date Type of Owner
LGND Ligand Pharmaceuticals Inc 2019-09-03 director
MACK Merrimack Pharmaceuticals Inc 2019-07-16 10 percent owner & other: See Explanation of Responses
ARLZQ Old API Wind-down Ltd 2017-05-19 director
NVLNF Novelion Therapeutics Inc 2017-05-15 director
IMMU Immunomedics Inc 2017-01-08 director
MYRX Myrexis Inc 2012-06-18 director
VXRT Vaxart Inc 2006-10-18 other: See Remarks Below
ANEB Anebulo Pharmaceuticals Inc 2022-04-21 director
HSAQ Health Sciences Acquisitions Corp 2 2023-01-26 director
OBIO Orchestra BioMed Holdings Inc 2023-07-20 director

Jason Aryeh Latest Holdings Summary

Jason Aryeh currently owns a total of 4 stocks. Among these stocks, Jason Aryeh owns 123,822 shares of Ligand Pharmaceuticals Inc (LGND) as of September 3, 2019, with a value of $8 Million and a weighting of 96.18%. Jason Aryeh owns 392,733 shares of Novelion Therapeutics Inc (NVLNF) as of May 15, 2017, with a value of $275,699 and a weighting of 3.12%. Jason Aryeh also owns 3,802 shares of Merrimack Pharmaceuticals Inc (MACK) as of July 16, 2019, with a value of $56,003 and a weighting of 0.63%. The other 1 stocks Myrexis Inc (MYRX) have a combined weighting of 0.07% among all his current holdings.

Latest Holdings of Jason Aryeh

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
LGND Ligand Pharmaceuticals Inc 2019-09-03 123,822 68.61 8,495,427
NVLNF Novelion Therapeutics Inc 2017-05-15 392,733 0.70 275,699
MACK Merrimack Pharmaceuticals Inc 2019-07-16 3,802 14.73 56,003
MYRX Myrexis Inc 2012-06-18 555,145 0.01 5,829

Holding Weightings of Jason Aryeh


Jason Aryeh Form 4 Trading Tracker

According to the SEC Form 4 filings, Jason Aryeh has made a total of 7 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years, including 7 buys and 0 sells. The most-recent trade in Ligand Pharmaceuticals Inc is the acquisition of 750 shares on September 3, 2019, which cost Jason Aryeh around $65,258.

According to the SEC Form 4 filings, Jason Aryeh has made a total of 0 transactions in Novelion Therapeutics Inc (NVLNF) over the past 5 years. The most-recent trade in Novelion Therapeutics Inc is the acquisition of 361 shares on May 15, 2017, which cost Jason Aryeh around $3,231.

According to the SEC Form 4 filings, Jason Aryeh has made a total of 2 transactions in Merrimack Pharmaceuticals Inc (MACK) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Merrimack Pharmaceuticals Inc is the acquisition of 302 shares on July 16, 2019, which cost Jason Aryeh around $1,643.

More details on Jason Aryeh's insider transactions can be found in the Insider Trading History of Jason Aryeh table.

Insider Trading History of Jason Aryeh

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jason Aryeh Trading Performance

GuruFocus tracks the stock performance after each of Jason Aryeh's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jason Aryeh is 4.93%. GuruFocus also compares Jason Aryeh's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jason Aryeh within 3 months outperforms 21 times out of 37 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jason Aryeh's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jason Aryeh

Average Return

-3.85%

Average return per transaction

Outperforming Transactions

57%

21 out of 37 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 6.23 4.93 9.04 -3.85 -8.27 -0.04
Relative Return to S&P 500(%) 4.57 0.47 3.33 -17.4 -24.86 -14.13

Jason Aryeh Ownership Network

Ownership Network List of Jason Aryeh

No Data

Ownership Network Relation of Jason Aryeh


Jason Aryeh Owned Company Details

What does Ligand Pharmaceuticals Inc do?

Who are the key executives at Ligand Pharmaceuticals Inc?

Jason Aryeh is the director of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include Chief Financial Officer Octavio Espinoza , CHIEF LEGAL OFFICER & Andrew Reardon , and CEO & President John L Higgins .

Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary

Over the past 18 months, Jason Aryeh made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 20,000 shares made by John L Higgins , a net sale of 10,852 shares made by John W Kozarich , and a net sale of 8,301 shares made by Stephen L Sabba .

In summary, during the past 3 months, insiders sold 2,033 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 0 shares, with a net sale of 2,033 shares. During the past 18 months, 41,289 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 37,289 shares.

Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Ligand Pharmaceuticals Inc Insider Transactions

No Available Data

Jason Aryeh Mailing Address

Above is the net worth, insider trading, and ownership report for Jason Aryeh. You might contact Jason Aryeh via mailing address: 11119 North Torrey Pines Road, Suite 200, La Jolla Ca 92037.

Discussions on Jason Aryeh

No discussions yet.